SCHEMBL1337013

SCHEMBL1337013

CN1CCN(c2ccc(N)c(C(=O)OC(C)(C)C)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
KDM4E B2RXH2 4/20 0.55
GAA P10253 2/20 0.55
PTK2B Q14289 2/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
RECQL P46063 1/20 0.55
IP6K1 Q92551 1/20 0.49
SIRT6 Q8N6T7 3/20 0.48
HTR6 P50406 3/20 0.44
ADRA2C P18825 2/20 0.43
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 1/20 0.43
GFER P55789 1/20 0.43
KMT2A Q03164 1/20 0.43
ESR2 Q92731 1/20 0.43
LMNA P02545 1/20 0.41
PARP1 P09874 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC8 Q9BY41 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL589358 0.90 KDM4E (0.51) MAPTKDM4EGAAPTK2BMAPK1
SCHEMBL3513419 0.85 MAPT (0.47) MAPTKDM4EGAAPTK2BMAPK1
SCHEMBL27170961 0.85 SIRT6 (0.64) MAPTKDM4EGAAPTK2BMAPK1
SCHEMBL5337053 0.84 SIRT6 (0.48) MAPTKDM4EGAAPTK2BMAPK1
SCHEMBL4356067 0.80 KDM4E (0.59) MAPTKDM4EGAAPTK2BMAPK1
SCHEMBL10739901 0.80 MAPT (0.59) MAPTKDM4EGAAPTK2BMAPK1
SCHEMBL941245 0.80 IP6K1 (0.74) MAPTKDM4EGAAPTK2BMAPK1
SCHEMBL1334925 0.80 SIRT6 (0.76) MAPTMAPK1SIRT6HTR6ALDH1A1
SCHEMBL21682956 0.80 MAPT (0.55) MAPTHTTIP6K1ALDH1A1KMT2A
Hydrochloric Acid SCHEMBL3503462 0.79 MAPT (0.58) MAPTKDM4EGAAPTK2BMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373626-B1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-08-24 EP disclosed
US-8354399-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-15 US disclosed
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-11-17 US disclosed
EP-2373626-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010069966-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, MAP3K3, MAP3K5 MAPT 2440/4885KDM4E 953/4885GAA 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.